PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
05-Aug-2024 Invitation: Straumann Group 2024 half-year results webcast Straumann Holding AG
05-Aug-2024 Medios expands „Advanced Therapies“ field and appoints Dr. Andreas Schmiede as Vice President Medios AG
05-Aug-2024 Davis Morgan Labs Unveils "How to Successfully Launch Your Monopoly Pharma Franchise: A Step-by-Step Guide" Davis Morgan Labs
05-Aug-2024 MorphoSys Completes Voluntary Delisting from the Frankfurt Stock Exchange and Nasdaq Global Market MorphoSys AG
05-Aug-2024 Relief Therapeutics Secures up to $11 Million from Royalty Sales Relief Therapeutics Holding SA
02-Aug-2024 BRUKINSA® Receives Positive Recommendation from NICE in U.K. for Patients with Marginal Zone Lymphoma BeiGene UK
01-Aug-2024 Thomas Pfaadt appointed as new Chief Financial Officer of Vita 34 AG Vita 34 AG
01-Aug-2024 Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update Immunic AG
01-Aug-2024 Galen announces exclusive licensing agreement with Italfarmaco for the distribution of Cariban® (doxylamine/pyridoxine) in Ireland for nausea and vomiting in pregnancy Galen Ltd
01-Aug-2024 Cannovum Cannabis AG: Far-reaching partnership with H.i. Greeny+ GmbH and H.i Competence Group for cannabis legalisation Cannovum Cannabis AG
31-Jul-2024 Galen announces exclusive licensing agreement with Italfarmaco for the distribution of Cariban® (doxylamine/pyridoxine) in Ireland for nausea and vomiting in pregnancy Galen Ltd
31-Jul-2024 MEDICLIN reports solid first half of 2024 MEDICLIN AG
31-Jul-2024 Transforming operational efficiency and sustainability: SCHOTT Pharma introduces nest design with more cavities for prefillable polymer syringes SCHOTT Pharma AG & Co. KGaA
30-Jul-2024 STRATEC REPORTS CHANGES IN FINANCE DIVISION STRATEC SE
30-Jul-2024 Biotest increases sales in the first half of 2024 by 35% to Euro 372 million Biotest AG
30-Jul-2024 AEVIS VICTORIA SA (AEVS:SW) achieved revenues of more than CHF 450 million in the first half-year 2024 AEVIS VICTORIA SA
30-Jul-2024 Formycon announces start of clinical phase III trial for Keytruda® biosimilar candidate FYB206 Formycon AG
29-Jul-2024 Spexis granted definitive moratorium status until 25 November 2024, subject to monthly progress report obligations, and which can be potentially extended at the request of the administrators. Spexis AG
26-Jul-2024 Formycon and Fresenius Kabi receive positive CHMP opinion for FYB202 (Ustekinumab), a biosimilar candidate to Stelara® Formycon AG
26-Jul-2024 Stelara® Biosimilar Candidate FYB202 (Ustekinumab) receives positive CHMP opinion from EMA Formycon AG